Clinical associations of the risk alleles of HLA-Cw6 and CCHCR1*WWCC in psoriasis

Acta Dermato-Venereologica

Volumn 87, Issue 2, 2007, Pages 127-134

  Suomela, Sari ^a   Kainu, Kati ^b   Onkamo, Päivi ^b   Tiala, Inkeri ^b   Himberg, Johan ^c   Koskinen, Lotta ^b,d   Snellman, Erna ^e   Karvonen, Seija Liisa ^a   Karvonen, Jaakko ^f   Uurasmaa, Tutta ^g   Reunala, Timo ^h   Kivekäs, Kristiina ^f   Jansen, Christer ^g   Holopainen, Päivi ^b   Elomaa, Outi ^b   Kere, Juha ^b,i   Saarialho Kere, Ulpu ^a,i,j  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c AALTO UNIVERSITY   (Finland)

^d FINNISH RED CROSS BLOOD SERVICE   (Finland)

^e PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁱ KAROLINSKA INSTITUTE   (Sweden)

^j STOCKHOLM SÖDER HOSPITAL   (Sweden)

more..

Author keywords

Anti psoriatic drugs; Guttate psoriasis; HLA C antigens; Nail; Psoriatic arthritis

Indexed keywords

HLA C ANTIGEN;

ADULT; AGED; ARTICLE; CHILD; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RISK FACTOR; SEX DIFFERENCE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; ARTHRITIS, PSORIATIC; CHILD; CHILD, PRESCHOOL; GENETIC PREDISPOSITION TO DISEASE; HLA-C ANTIGENS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PSORIASIS; SEX FACTORS;

EID: 34047124223     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-0184     Document Type: Article

References (40)

1. Lomholt G. Psoriasis: prevalence, spontaneous course, and genetics: a census study on the prevalence of skin diseases on Faroe Islands. Copenhagen: GEC Gad, 1963.
2. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314-320.
3. Williams RC, McKenzie AW, Roger JH, Joysey VC. HL-A antigens in patients with guttate psoriasis. Br J Dermatol 1976; 95: 163-167.
4. Lavaroni G, Kokelj F, Pauluzzi P, Trevisan G. The nails in psoriatic arthritis. Acta Derm Venereol 1994; suppl 186: 113.
5. Raychaudhuri SP, Gross J. A comparative study of pediatric onset psoriasis with adult onset psoriasis. Pediatr Dermatol 2000; 17: 174-178.
6. Poikolainen K, Reunala T, Karvonen J. Smoking, alcohol and life events related to psoriasis among women. Br J Dermatol 1994; 130: 473-177.
7. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998; 16: 333-351.
8. Naldi L, Peli L, Parazzini F, Carrel CF; Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. J Am Acad Dermatol 2001; 44: 433-438.
9. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005; 125: 61-67.
10. Telfer NR, Chalmers RJ, Whale K, Colman G. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992; 132: 717-718.
11. Gudjonsson JE, Thorarinsson AM, Sigurgeirsson B, Kristinsson KG, Valdimarsson H. Streptococcal throat infections and exacerbation of chronic plaque psoriasis: a prospective study. Br J Dermatol 2003; 149: 530-534.
12. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
13. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64 suppl 2: ii30-36.
14. Asumalahti K, Laitinen T, Itkonen-Vatjus R, Lokki ML, Suomela S, Snellman E, et al. A candidate gene for psoriasis near HLA-C, HCR (Pg8), is highly polymorphic with a disease-associated susceptibility allele. Hum Mol Genet 2000; 9: 1533-1542.
15. Asumalahti K, Veal C, Laitinen T, Suomela S, Allen M, Elomaa, et al. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. Hum Mol Genet 2002; 11: 589-597.
16. Chang YT, Shiao YM, Chin PJ, Liu YL, Chou FC, Wu S, et al. Genetic polymorphisms of the HCR gene and a genomic segment in close proximity to HLA-C are associated with patients with psoriasis in Taiwan. Br J Dermatol 2004; 150: 1104-1111.
17. Corbi N, Bruno T, De Angelis R, Di Padova M, Libri V, Di Certo MG, et al. RNA Polymerase II subunit 3 is retained in the cytoplasm by its interaction with HCR, the psoriasis vulgaris candidate gene product. J Cell Sci 2005; 118: 4253-1260.
18. Elomaa O, Majuri I, Suomela S, Asumalahti K, Jiao H, Mirzaei Z, et al. Transgenic mouse models support HCR as an effector gene in the PSORS1 locus. Hum Mol Genet 2004; 13: 1551-1561.
19. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
20. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
21. Tonks S, Marsh SGE, Bunce M, Bodmer JG. Molecular typing for HLA class I using ARMS-PCR: Further development following the 12th International Histocompatibility Workshop. Tissue Antigens 1999; 53: 175-183.
22. Hand D, Mannila H, Smyth P, editors. Principles of data mining. Chapter: Data analysis and Uncertainty, Hypothesis Testing. Cambridge, MA: MIT Press, 2001: pp. 93-139.
23. Gudjonsson JE, Karason A, Antonsdottir AA, Runarsdottir EH, Gulcher JR, Stefansson K, Valdimarsson H. HLA-Cw6-positive and HLA-Cw6-negative patients with psoriasis vulgaris have distinct clinical features. J Invest Dermatol 2002; 118: 362-365.
24. Mallbris L, Larsson P, Bergqvist S, Vingard E, Granath F, Stahle M. Psoriasis phenotype at disease onset: clinical characterization of 400 adult cases. J Invest Dermatol 2005; 124: 499-504.
25. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 2003; 120: 627-632.
26. Swanbeck G, Inerot A, Martinsson T, Wahlstrom J, Enerback C, Enlund F, Yhr M. Age at onset and different types of psoriasis. Br J Dermatol 1995; 133: 768-773.
27. Stuart P, Malick F, Nair RP, Henseler T, Lim HW, Jenisch S, et al. Analysis of phenotypic variation in psoriasis as a function of age at onset and family history. Arch Dermatol Res 2002; 294: 207-213.
28. Ikäheimo I, Tiilikainen A, Karvonen J, Silvennoinen-Kassinen S. HLA risk haplotype Cw6,DR7,DQA 1 *0201 and HLA-Cw6 with reference to the clinical picture of psoriasis vulgaris. Arch Dermatol Res 1996; 288: 363-365.
29. Gudjonsson JE, Karason A, Runarsdottir EH, Antonsdottir AA, Hauksson VB, Jonsson HH, et al. Distinct clinical differences between HLA-Cw*0602 positive and negative psoriasis patients - an analysis of 1019 HLA-C- and HLA-B-typed patients. J Invest Dermatol 2006; 126: 740-745.
30. Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, McHugh N. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 2002; 41: 525-530.
31. Gladman DD, Farewell VT, Pellett F, Schentag C, Rahman P. HLA is a candidate region for psoriatic arthritis. Evidence for excessive HLA sharing in sibling pairs. Hum Immunol 2003; 64: 887-889.
32. Karason A, Gudjonsson JE, Upmanyu R, Antonsdottir AA, Hauksson VB, Runasdottir EH, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16q: evidence for imprinting. Am J Hum Genet 2002; 72: 125-131.
33. Choi EH, Brown BE, Crumrine D, Chang S, Man MQ, Elias PM, Feingold KR. Mechanisms by which psychologic stress alters cutaneous permeability barrier homeostasis and stratum corneum integrity. J Invest Dermatol 2005; 124: 587-595.
34. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001; 303: 33-39.
35. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-986.
36. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Ståhle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-230.
37. Veal CD, Capon F, Allen MH, Heath EK, Evans JC, Jones A, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet 2002; 71: 554-564.
38. Holm SJ, Sanchez F, Carlen LM, Mallbris L, Ståhle M, O'Brien KP. HLA-Cw*0602 associates more strongly to psoriasis in the Swedish population than variants of the novel 6p21.3 gene PSORS1C3. Acta Derm Venereol 2005; 85: 2-8.
39. Karvonen J, Tiilikainen A, Lassus A. HL-A antigens in patients with persistent palmoplantar pustulosis and pustular psoriasis. Ann Clin Res 1975; 7: 112-115.
40. Muto M, Ohmura A, Hamamoto Y, Konishi Y, Shiozawa S, Youn JI, et al. Generalized pustular psoriasis: strategy for identification of psoriasis susceptibility gene. Arch Dermatol Res 2003; 295: S60-S62.